Xbrane Biopharma AB (XBRANE) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Camurus AB

BioArctic AB

Swedencare AB

Calliditas Therapeutics AB

Xbrane Biopharma AB

Egetis Therapeutics AB

Hansa Biopharma AB

Vicore Pharma Holding AB

Xspray Pharma AB

Infant Bacterial Therapeutics AB

FluoGuide A/S

Why is Xbrane Biopharma AB ?

Flat results in Mar 25

CASH AND EQV(HY) Lowest at SEK 149.04 MM
DEBT-EQUITY RATIO (HY) Highest at 57.75 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -56.88%, its profits have risen by 72.4%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -56.88% returns in the last 1 year, the stock has also underperformed OMX Stockholm 30 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Xbrane Biopharma AB for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Xbrane Biopharma AB

-100.0%

0.33

9382.70%

OMX Stockholm 30

8.45%

0.44

18.11%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

191.39%

EBIT Growth (5y)

15.23%

EBIT to Interest (avg)

-67.28

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.58

Sales to Capital Employed (avg)

0.43

Tax Ratio

8.45%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.69

EV to EBIT

-77.01

EV to EBITDA

37.51

EV to Capital Employed

1.66

EV to Sales

2.50

PEG Ratio

Dividend Yield

ROCE (Latest)

-2.16%

ROE (Latest)

-24.41%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

32What is working for the Company

OPERATING CASH FLOW(Y)

Highest at SEK -89.16 MM

ROCE(HY)

Highest at -48.71%

OPERATING PROFIT(Q)

Highest at SEK 24.05 MM

PRE-TAX PROFIT(Q)

Highest at SEK 19.25 MM

RAW MATERIAL COST(Y)

Fallen by -70.87% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 9.11%

NET SALES(Q)

Highest at SEK 93.24 MM

NET PROFIT(Q)

Highest at SEK 19.25 MM

EPS(Q)

Highest at SEK 0.01

-2What is not working for the Company

CASH AND EQV(HY)

Lowest at SEK 149.04 MM

DEBT-EQUITY RATIO (HY)

Highest at 57.75 %

Here's what is working for Xbrane Biopharma AB

Net Sales

At SEK 93.24 MM has Grown at 87.67%

over average net sales of the previous four periods of SEK 49.68 MM

MOJO Watch

Near term sales trend is very positive

Net Sales (SEK MM)

Operating Profit

Highest at SEK 24.05 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (SEK MM)

Pre-Tax Profit

Highest at SEK 19.25 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (SEK MM)

Pre-Tax Profit

At SEK 19.25 MM has Grown at 130.38%

over average net sales of the previous four periods of SEK -63.36 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (SEK MM)

Net Profit

At SEK 19.25 MM has Grown at 129.05%

over average net sales of the previous four periods of SEK -66.25 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (SEK MM)

Operating Cash Flow

Highest at SEK -89.16 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (SEK MM)

Net Sales

Highest at SEK 93.24 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (SEK MM)

Net Profit

Highest at SEK 19.25 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (SEK MM)

EPS

Highest at SEK 0.01

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (SEK)

Debtors Turnover Ratio

Highest at 9.11%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -70.87% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Xbrane Biopharma AB

Cash and Eqv

Lowest at SEK 149.04 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 57.75 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio